The totality of the data and current standard of care recommended by international guidelines for patients with HER2-positive early breast cancer at high risk of recurrence is 1 year of pertuzumab–trastuzumab therapy, regardless of the timing of surgery17,18. The gene discussed is ERBB2; the disease is breast carcinoma.